Brief: FDA Accepts Arcutis’ Supplemental New Drug Application For Zoryve
24/09/2024 13:04
Sept 24 (Reuters) - Arcutis Biotherapeutics Inc
ARQT.O :
* FDA ACCEPTS ARCUTIS’ SUPPLEMENTAL NEW DRUG APPLICATION FOR
ZORYVE® (ROFLUMILAST) FOAM FOR THE TREATMENT OF SCALP AND BODY
PSORIASIS IN ADULTS AND ADOLESCENTS AGES 12 AND OVER
* ARCUTIS BIOTHERAPEUTICS INC - FDA SETS PDUFA TARGET ACTION
DATE
OF MAY 22, 2025
Source text for Eikon: ID:nGNXbvzhbl
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf